Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 19;8(4):541.
doi: 10.3390/jcm8040541.

Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study

Affiliations

Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study

Guido A Gualdoni et al. J Clin Med. .

Abstract

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening condition clinically presenting as SIRS (Systemic Inflammatory Response Syndrome). However, there is no comprehensive data concerning diagnostic algorithms, prevalence, outcome and biomarker performance in SIRS patients. We conducted a prospective observational cohort study on 451 consecutive patients fulfilling ≥2 SIRS criteria. The Hscore and the HLH-2004 criteria were used to determine the presence of sHLH, and the correlation of the screening-biomarkers ferritin, sCD25, and sCD163 with both scores was assessed. Out of 451 standard-care SIRS patients, five patients had high Hscores (≥169), suggesting incipient or HLH-like disease, and these patients were in urgent need for intensified therapy. However, none of these patients fulfilled five HLH-2004 criteria required for formal diagnosis. From the studied biomarkers, ferritin correlated strongest to both the HLH-2004 criteria and the Hscore (rs = 0.72, 0.41, respectively), and was the best predictor of 30-day survival (HR:1.012 per 100 μg/L, 95% CI: 1.004-1.021), when adjusted for patient's age, sex, bacteremia and malignant underlying-disease. Also, the HLH-2004 (HR per point increase: 1.435, 95% CI: 1.1012-2.086) and the Hscore (HR per point increase:1.011, 95% CI: 1.002-1.020) were independent predictors of 30-day-survival. The Hscore detected patients in hyperinflammatory states requiring urgent therapy escalation. Degrees of hyperinflammation, as assessed by ferritin and both HLH scores, are associated with worse outcomes.

Keywords: HLH; SIRS; hemophagocytic lymphohistiocytosis; hemophagocytosis; outcome; prevalence; survival.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Correlation between the HLH-2004 criteria and the Hscore; Boxplots of the corresponding score are displayed on the opposite side of the plot, r = Spearman rank correlation coefficient.
Figure 2
Figure 2
30-day and 1095-day survival with respect to ferritin.
Figure 3
Figure 3
Correlations between sCD25, sCD163 and Ferritin the studied HLH-scores; Boxplots of the corresponding score are displayed on the opposite side of the plot, r = Spearman rank correlation coefficient.

Similar articles

Cited by

References

    1. Sepulveda F.E., de Saint Basile G. Hemophagocytic syndrome: Primary forms and predisposing conditions. Curr. Opin. Immunol. 2017;49:20–26. doi: 10.1016/j.coi.2017.08.004. - DOI - PubMed
    1. Jaffe R. The histiocytoses. Clin. Lab. Med. 1999;19:135–155. doi: 10.1016/S0272-2712(18)30132-X. - DOI - PubMed
    1. Janka G.E., Lehmberg K. Hemophagocytic lymphohistiocytosis: Pathogenesis and treatment. Hematol. Am. Soc. Hematol. Educ. Program. 2013;2013:605–611. doi: 10.1182/asheducation-2013.1.605. - DOI - PubMed
    1. Kleynberg R.L., Schiller G.J. Secondary hemophagocytic lymphohistiocytosis in adults: An update on diagnosis and therapy. Clin. Adv. Hematol. Oncol. 2012;10:726–732. - PubMed
    1. Morimoto A., Nakazawa Y., Ishii E. Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management. Pediatr. Int. 2016;58:817–825. doi: 10.1111/ped.13064. - DOI - PubMed

LinkOut - more resources